I am a senior biotech and pharma strategist with over 20 years of experience across medical affairs, clinical development, external innovation, portfolio strategy, and venture-facing due diligence. My background spans oncology, hematology, rare diseases, RNA therapeutics, CNS, dermatology, regenerative medicine, and longevity biology. I have held leadership roles in global and regional organizations, including Celgene, Biogen, Alnylam, Mayne Pharma, Novartis-related innovation activities, and biotech ventures, where I contributed to launch readiness, medical affairs build-up, KOL engagement, patient identification, early access, evidence generation, and cross-functional execution. As a consultant and innovation expert, I support startups, biotechs, investors, accelerators, and funding bodies in translating complex science into credible development, medical, and investment strategies. My work combines deep scientific expertise, operational pharma experience, strategic judgment, and the
Founder and Principal
Siham Ceballos
Biotech/pharma strategy expert: medical affairs, clinical development, due diligence, EU launch readiness.
BioArtemis GmbH, Innosuisse, GCLS
LinkedIn profileAreas of expertise
- Business development, Partnerships, Funding
- Commercialization and market access
- Due Diligence
- Medical
- Medical Affairs
- Portfolio Management
- Prelaunch and Launch
- Research and clinical development